about
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsAnti-α4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infectionExclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.α4-Integrin Antibody Treatment Blocks Monocyte/Macrophage Traffic to, Vascular Cell Adhesion Molecule-1 Expression in, and Pathology of the Dorsal Root Ganglia in an SIV Macaque Model of HIV-Peripheral Neuropathy.Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Immunotoxicity profile of natalizumab.
@en
Immunotoxicity profile of natalizumab.
@nl
type
label
Immunotoxicity profile of natalizumab.
@en
Immunotoxicity profile of natalizumab.
@nl
prefLabel
Immunotoxicity profile of natalizumab.
@en
Immunotoxicity profile of natalizumab.
@nl
P2093
P2860
P1476
Immunotoxicity profile of natalizumab.
@en
P2093
Carolyn Gasper
George Shopp
Janet Clarke
Joyce Nelson
Ken Draper
Nancy G Wehner
Suezanne Parker
P2860
P304
P356
10.1080/15476910902977381
P577
2009-06-01T00:00:00Z